MHRA Details Regulatory Arrangements for No-Deal Brexit

Drug Industry Daily
The UK’s Medicines and Healthcare products Regulatory Agency released new details of how it plans to continue drug regulatory operations if there is no Brexit deal by March 29 — including new fees to cover its added regulatory burden.

To View This Article:


Subscribe To Drug Industry Daily